The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2022 | Novel Targets: PIKfyve, RAS, the epigenome & PROTAC therapy
In this session, we take a look at the very latest in novel targets. The experts discuss introducing a pro-survival gene into CARs, targeting RAS, PIKfyve, and epigenomics, the epigenetics of resistance to proteasome and IMiD drugs as well as PROTAC therapy for difficult manipulate targets. Lawrence Boise, PhD, Winship Cancer Institute of Emory University, Atlanta, GA, chairs this session with Paola Neri, MD, PhD, University of Calgary, Calgary, Canada. This discussion took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
